Question 1

What is COVID-19–associated multisystem inflammatory syndrome in children?

Accepted Answer

COVID-19–associated multisystem inflammatory syndrome in children is a serious inflammatory condition that arises in some children following infection with SARS-CoV-2. It shares features with Kawasaki disease and can affect multiple organ systems, including the heart and blood vessels. Although precise prevalence estimates are not available, the condition is considered uncommon and is primarily seen in the pediatric population. Not all children develop the full spectrum of symptoms, and severity varies considerably.

Question 2

What are the symptoms of COVID-19–associated multisystem inflammatory syndrome in children?

Accepted Answer

The clinical presentation of this syndrome typically includes persistent fever and signs of systemic inflammation, which may progress to affect the heart with myocardial injury or shock, and in some cases can lead to coronary artery abnormalities. Children often present with symptoms that prompt evaluation for multisystem involvement, and the range of manifestations may include gastrointestinal, dermatologic, and circulatory issues. That not all individuals experience all features, and the severity of symptoms can vary widely between children.

Question 3

What causes COVID-19–associated multisystem inflammatory syndrome in children?

Accepted Answer

This condition appears to result from an abnormal inflammatory response triggered by a SARS-CoV-2 infection. The precise genetic basis remains under investigation, and current evidence suggests that it is not inherited but instead is linked to environmental and immune-related factors following viral exposure. As research continues, families are encouraged to discuss potential risk factors and concerns with their healthcare team.

Question 4

How is COVID-19–associated multisystem inflammatory syndrome in children diagnosed?

Accepted Answer

Diagnosis is made through a comprehensive clinical evaluation that assesses symptoms, laboratory markers of inflammation, and a history of recent SARS-CoV-2 exposure. While molecular genetic testing is the gold standard for confirming many inherited conditions, in this case the diagnosis is based on clinical findings and specialized laboratory tests. Because the symptoms of this syndrome can overlap with other conditions such as Kawasaki disease, careful evaluation and exclusion of alternative diagnoses is essential.

Question 5

Are there treatments for COVID-19–associated multisystem inflammatory syndrome in children?

Accepted Answer

Currently, management focuses on supportive care and symptom management tailored to the individual child. In clinical practice, a multidisciplinary team typically provides care to address the various manifestations of the syndrome, with treatments aimed at controlling inflammation and supporting affected organ systems. Patients should discuss treatment options with their healthcare team to determine which therapies may be appropriate for their specific situation, and ongoing follow-up is important to monitor recovery and identify any emerging complications.

Question 6

Are there clinical trials for COVID-19–associated multisystem inflammatory syndrome in children?

Accepted Answer

Yes, there are currently 2 active clinical trials for COVID-19–associated multisystem inflammatory syndrome in children registered on ClinicalTrials.gov. Clinical trials test new treatments, procedures, or approaches. Your healthcare provider can help determine if a trial might be appropriate for your situation. Visit the Treatment section of this page for more details.

Question 7

Where can I find support for COVID-19–associated multisystem inflammatory syndrome in children?

Accepted Answer

Patient advocacy organizations for COVID-19–associated multisystem inflammatory syndrome in children include Innovation Fund Denmark. These organizations can provide information, connect you with other families, and help navigate care. Visit the Support section of this page for full details and contact information.

Question 8

What complications can arise from COVID-19–associated multisystem inflammatory syndrome in children?

Accepted Answer

COVID-19–associated multisystem inflammatory syndrome in children can lead to serious complications, particularly affecting the heart. Some children may experience myocardial injury, shock, or even coronary artery abnormalities. It's important for families to monitor their child's symptoms closely and seek medical attention if they notice any concerning changes.

Question 9

How does COVID-19–associated multisystem inflammatory syndrome in children affect daily life?

Accepted Answer

Living with COVID-19–associated multisystem inflammatory syndrome in children can be challenging. Children may need to limit physical activities during recovery and attend regular follow-up appointments to monitor their health. Families should work closely with healthcare providers to manage symptoms and ensure the child receives appropriate care.

Question 10

What is the long-term prognosis for children with COVID-19–associated multisystem inflammatory syndrome in children?

Accepted Answer

The long-term prognosis for children with COVID-19–associated multisystem inflammatory syndrome varies. Many children recover well, especially with timely supportive care, but some may need ongoing monitoring for potential complications. Families are encouraged to stay in touch with healthcare specialists to ensure their child's health is regularly assessed.

Question 11

Are there specific specialists that should be involved in the care of a child with COVID-19–associated multisystem inflammatory syndrome in children?

Accepted Answer

Yes, a multidisciplinary team of specialists is often involved in the care of children with COVID-19–associated multisystem inflammatory syndrome. This team may include pediatricians, cardiologists, and other healthcare providers who can address the various symptoms and complications. Families should discuss the best care options with their healthcare team to ensure comprehensive support.

NCT ID	Title	Phase	Sponsor	Status
[NCT04830852](https://clinicaltrials.gov/study/NCT04830852)	Pediatric COVID Outcomes Study (PECOS)	—	Children's National Research Institute	ACTIVE_NOT_RECRUITING
[NCT05287412](https://clinicaltrials.gov/study/NCT05287412)	Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children	—	Carelon Research	UNKNOWN
[NCT05582512](https://clinicaltrials.gov/study/NCT05582512)	Clinical Characteristics and Long Term Impact on Pediatric COVID-19 in Taiwan	—	National Taiwan University Hospital	UNKNOWN
[NCT07126028](https://clinicaltrials.gov/study/NCT07126028)	Quality of Life in Children After Multisystem Inflammatory Syndrome in Children	—	Kristina Lah Tomulić	UNKNOWN
[NCT04278404](https://clinicaltrials.gov/study/NCT04278404)	Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)	—	Duke University	RECRUITING

Research Type	Count	% of Total
Disease patterns and progression	56	31%
Research summaries	45	25%
Laboratory research	28	15%
Patient case studies	20	11%
Testing and diagnosis research	19	10%
Clinical study results	11

Kisho

COVID-19–associated multisystem inflammatory syndrome in children

Overview

Diagnosis

Research Landscape

Recent Publications

Patient Support

Patient Advocacy Groups

Medical References

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Latest News & Developments

A longitudinal comparative analysis of serum metabolomic signatures in children with SARS-CoV-2 infection and MIS-C.

Endomyocardial calcification with pulmonary and systemic hypertension in a term neonate with multisystem inflammatory syndrome of newborn (MIS-N).

2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now? - BioSpace

Effectiveness of 2024–2025 COVID-19 Vaccines in Children in the United States — VISION, August 29, 2024–September 2, 2025

Nursing Home Data Dashboard

COVID-19–associated multisystem inflammatory syndrome in children

Overview

Diagnosis

Research Landscape

Recent Publications

Patient Support

Patient Advocacy Groups

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is COVID-19–associated multisystem inflammatory syndrome in children?

What are the symptoms of COVID-19–associated multisystem inflammatory syndrome in children?

What causes COVID-19–associated multisystem inflammatory syndrome in children?

How is COVID-19–associated multisystem inflammatory syndrome in children diagnosed?

Are there treatments for COVID-19–associated multisystem inflammatory syndrome in children?

Are there clinical trials for COVID-19–associated multisystem inflammatory syndrome in children?

Where can I find support for COVID-19–associated multisystem inflammatory syndrome in children?

What complications can arise from COVID-19–associated multisystem inflammatory syndrome in children?

How does COVID-19–associated multisystem inflammatory syndrome in children affect daily life?

What is the long-term prognosis for children with COVID-19–associated multisystem inflammatory syndrome in children?

Are there specific specialists that should be involved in the care of a child with COVID-19–associated multisystem inflammatory syndrome in children?

Latest News & Developments

A longitudinal comparative analysis of serum metabolomic signatures in children with SARS-CoV-2 infection and MIS-C.

Endomyocardial calcification with pulmonary and systemic hypertension in a term neonate with multisystem inflammatory syndrome of newborn (MIS-N).

2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now? - BioSpace

Effectiveness of 2024–2025 COVID-19 Vaccines in Children in the United States — VISION, August 29, 2024–September 2, 2025

Nursing Home Data Dashboard